Will New Actavis-Allergan Entity Lead to Be in the World Top 10 Drugmakers Companies?

24/11/2014 - 2 minutes

The US pharmaceutical company Allergan, known for their Botox, agreed an Actavis bid of 53 billion euros, they permanently passed up the proposition of Valeant Pharmaceuticals International and the activist investor William Ackman.

The Allergan-Actavis entity will have a diversified portfolio of medicines and generic, especially in dermatology, gynecology and ophthalmology. It should generate about €19 billion in sales annually, making it one of the world’s leading pharmaceutical companies.

The Botox whose active ingredient is the botulinum toxin, is a substance produced by bacteria which paralyzes the muscles. The market is exploding worldwide, especially in the US, where the injection to erase facial wrinkles was approved in 2002 by the FDA (Food and Drugs Administration). More than 4 million botox injections were performed in 2012 in the United States and it is still increasing.

Moreover, Allergan had previously rebuffed Valeant Pharmaceuticals and activist investor William Ackman’s Pershing Square Capital Management, which together had been pursuing it for months.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!